Trials / Not Yet Recruiting
Not Yet RecruitingNCT07291050
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is the first-in-human clinical study of TQB3217, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3217 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3217Tablets | TQB3217 Tablets are ubiquitin specific peptidase 1(USP1)-t inhibitor. |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2025-12-18
- Last updated
- 2025-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07291050. Inclusion in this directory is not an endorsement.